Wegovy 7.2mg: Understanding The New Dosage Option

Article Summary

• Wegovy 7.2mg is a newly approved, higher-strength dose that works in the same way as existing Wegovy doses, but delivers greater weight-loss effects for some people with obesity.
• Clinical trials show increased effectiveness, with an average weight loss of 20.7% over 72 weeks. About 1 in 3 patients lost more than 25% of their body weight.
• Side effects are similar to lower doses but may be more common. Wegovy 7.2mg should only be used under medical supervision and may not be suitable for everyone.

If you’re taking Wegovy for weight loss or you’re considering starting, you may have heard that a new, higher 7.2 mg dose of Wegovy is now available. In this blog post, we’ll unpack everything you need to know about the new dose.

What Is Wegovy?

Before we dive into the details of the new Wegovy dose, it’s important to understand how it works. Wegovy is a once-weekly, injectable weight loss medication that contains the active ingredient semaglutide (the same ingredient as Ozempic). It’s part of a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, more commonly referred to as GLP-1s.

GLP-1 medications work by mimicking the natural GLP-1 hormone that is released in your gut after eating. They aid weight loss in a few different ways:

• Slowing stomach (gastric) emptying, helping you feel fuller for longer. [1]
• Targeting the reward centre in your brain to reduce your appetite. [1]
• Regulating your blood sugar levels to prevent cravings. [1]

Difference Between 7.2 mg and Other Wegovy Dosages

The new 7.2 mg Wegovy dose works in the same way as all other Wegovy doses, but it is significantly stronger than the current maximum Wegovy dose that is available (2.4 mg).

Clinical Trials and Efficacy

In clinical trials, patients taking 7.2 mg of Wegovy lost 20.7% of their body weight compared to 17.5% with the current 2.4 mg dose over 72 weeks. Plus, 33.2% of patients on the higher dose lost over 25% of their body weight. [1,2]

Comparison with Other Treatments

When we compare Wegovy 7.2 mg with other GLP-1 medications like Mounjaro (tirzepatide), it performs remarkably well. In trials, patients taking tirzepatide lost 22.5% of their starting weight over 72 weeks, which is only slightly more than with Wegovy 7.2 mg.

Notably, 33.2% of patients on the higher Wegovy dose lost more than 25% of their body weight, meaning it is now one of the most effective GLP-1 medications on the market.

Regulatory Status

As of January 2026, a 7.2 mg once-weekly dose of Wegovy is approved for use in the UK for the treatment of obesity. This follows a detailed review by medicines regulators, who assess whether new treatments are safe and appropriate for use. [3]

This approval means that Wegovy 7.2 mg has been carefully evaluated and can now be prescribed in the UK when it is clinically suitable. However, it won’t be the right option for everyone.

It’s important to use Wegovy only as prescribed by a qualified healthcare professional. You should never increase your dose on your own or try to obtain higher doses without medical advice, as this can increase the risk of side effects and may be unsafe. Your prescriber will help decide when, or if, moving to a higher dose makes sense for you.

Side Effects and Safety Profile

Because the new dose is a higher concentration of semaglutide, the side effect profile is the same as that of lower doses. Research has shown that digestive side effects remain the most common with Wegovy 7.2 mg, but, as expected, slightly more people stopped taking medication due to side effects. [2]

Here’s what we know about side effects from the STEP UP clinical trial so far:

• Around 1 in 3 patients taking Wegovy 7.2 mg experienced nausea
• Around 1 in 6 patients experienced diarrhoea
• Around 1 in 6 patients experienced vomiting
• Around 1 in 7 patients experienced constipation

A side effect called 'dysaesthesia' was also noted in the STEP UP trial, occurring in nearly 1 in 4 of participants taking Wegovy 7.2 mg. It involves sensations of tingling, numbness and burning. It's a neurological symptom, often affecting the skin, but can also involve other senses like touch.

Finally, it’s essential to remember that serious side effects of GLP-1 treatments, such as pancreatitis and severe allergic reactions, may occur with this new dosage. You can learn more about what to look out for and when to seek medical attention here.

Considerations for Current Wegovy Users

When transitioning to Wegovy 7.2 mg, it’s important to do so under the supervision of a healthcare professional. This higher dose should only be used after you’ve successfully tolerated lower doses of Wegovy, such as 2.4 mg, ensuring your body adjusts safely and side effects are minimised.

Price of Wegovy 7.2 mg

The price of the new dose is £279.99. It is more expensive than the previous highest dose of Wegovy (2.4 mg semaglutide) because the new dose contains significantly more medication, and demand is expected to be high.

Ready to Start Your Weight Loss Journey?

At MedExpress, we’ll help determine which medication is best suited to your needs, based on your medical history and weight loss goals. Learn more about your options here.

References

1. Wilding JPH, Batterham RL, Calanna S. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine [Internet]. 2021 Feb 10;384(11):989–1002. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Wharton S, Freitas P, Jøran Hjelmesæth, Kabisch M, Kandler K, Ildiko Lingvay, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology [Internet]. 2025 Sep 1; Available from: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00226-8/abstract
3. Medicines and Healthcare products Regulatory Agency. Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only [Internet]. GOV.UK; 2026 Jan 16 [cited 2026 Jan 20]. Available from: https://www.gov.uk/government/news/medicines-regulator-approves-up-to-72mg-dose-of-semaglutidewegovy-for-patients-with-obesity-only